Axonyx Phenserine May Be First Alzheimer's Drug Targeting Beta-Amyloid
Executive Summary
Axonyx' phenserine could be the first Alzheimer's disease agent targeting beta-amyloid plaques filed at FDA as companies look to move beyond the symptom relief offered by current therapies